Description

Olanib 150 mg (Olaparib) – Targeted Cancer Therapy by Everest Pharmaceuticals

Product Name: Olanib 150 mg
Generic Name: Olaparib
Manufacturer: Everest Pharmaceuticals Ltd.
Strength: 150 mg per tablet
Pack Size: 120 tablets (HDPE container)

Overview

Olanib 150 mg (Olaparib) is a PARP inhibitor prescribed for the treatment of advanced cancers linked to BRCA1, BRCA2, and HRR gene mutations. It works by blocking PARP enzymes that repair damaged DNA in cancer cells, leading to cell death. This makes Olanib a highly effective option for patients with specific genetic mutations.

Indications – What Olanib 150 mg is used for:

• Ovarian Cancer: Maintenance therapy for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

• Breast Cancer: Treatment of HER2-negative metastatic breast cancer with germline BRCA mutation.

• Pancreatic Cancer: Management of metastatic pancreatic cancer with BRCA mutations, previously treated with platinum-based chemotherapy.

• Prostate Cancer: Treatment of metastatic castration-resistant prostate cancer with BRCA1, BRCA2, or other HRR gene mutations.

Mechanism of Action

• PARP Inhibition: Olaparib blocks PARP enzymes involved in DNA repair.

• Synthetic Lethality: Tumor cells with BRCA1/BRCA2 mutations are highly sensitive, leading to targeted cancer cell death.

• Cancer Cell Control: Helps slow disease progression in advanced and metastatic cancers.

Dosage & Administration

• Recommended Dose: 300 mg daily (two 150 mg tablets) taken twice daily, total 600 mg/day.

• Schedule: Continue until disease progression or unacceptable toxicity.

• Administration: Swallow tablets whole with water. Do not chew, crush, or dissolve. Can be taken with or without food.

• Timing: Twice daily at ~12-hour intervals.

Contraindications & Warnings

• Contraindicated in patients with severe renal or hepatic impairment.

• Avoid in case of hypersensitivity to Olaparib or excipients.

• Use with caution in patients at risk of myelosuppression, gastrointestinal toxicity, or pneumonitis.

• Not recommended during pregnancy – may cause fetal harm.

Drug & Food Interactions

• Avoid CYP3A inducers: Rifampicin, phenytoin, carbamazepine, St. John’s Wort.

• Avoid CYP3A inhibitors: Clarithromycin, ketoconazole, itraconazole, voriconazole, fluconazole.

• Dietary Restrictions: Grapefruit, grapefruit juice, Seville oranges should be avoided.

• Alcohol: Limited consumption advised, as interactions are not fully known.

Side Effects

Common side effects of Olanib 150 mg include:

• Nausea, vomiting, fatigue, diarrhea

• Anemia, neutropenia, thrombocytopenia

• Headache, dizziness, decreased appetite

• Taste changes (dysgeusia)

• Mouth sores and gastrointestinal discomfort

Storage Instructions

• Store at room temperature.

• Keep in a dry place, away from direct sunlight.

• Keep out of reach of children.

Why Choose Olanib 150 mg?

• Trusted manufacturer: Everest Pharmaceuticals Ltd.

• Targeted therapy for cancers linked to BRCA1/BRCA2 mutations

• Convenient oral administration with proven clinical efficacy